Kelsey Goodwin
Stock Analyst at Guggenheim
(0)
# 4196
Out of 5,269 analysts
15
Total ratings
44.44%
Success rate
-7.03%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Genelux | Initiates Coverage On: Buy | 8 | 4.15 | 92.77% | 1 | Oct 29, 2024 | |
Nuvalent | Maintains: Strong Buy | 99 105 | 74.27 | 41.38% | 2 | Sep 16, 2024 | |
UroGen Pharma | Initiates Coverage On: Buy | 40 | 9.35 | 327.81% | 1 | Aug 22, 2024 | |
Macrogenics | Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 31, 2024 | |
2seventy bio | Downgrades: Neutral | n/a | n/a | n/a | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | n/a | n/a | n/a | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 15 | 0.66 | 2172.73% | 1 | Oct 31, 2022 |